OXIGENE TO BEGIN ONCOLOGY CLINICAL TRIAL

OxiGene will initiate a clinical trial with its lead vascular disrupting compound,
Combretastatin A4 Phosphate (CA4P). The Phase Ib study will evaluate CA4P in
combination therapy with Avastin (bevacizumab).

The trial follows preclinical data that showed that the combination of CA4P
with the anti-angiogenic drug Avastin, produced significant antitumor activity.
This data showed that treatment with Avastin or CA4P alone resulted in tumor
growth delays of eight days and six days, respectively. The data also showed
that CA4P was effective at causing extensive vasculature damage and tumor cell
death in the central regions of solid tumors.